Consensus Anika Therapeutics, Inc.

Stocks

ANIK

US0352551081

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
21.42 ^USD	+1.56%		+7.21%	+122.89%

09-18	B. Riley Adjusts Anika Therapeutics Price Target to $23 From $21, Maintains Buy Rating	MT
07-30	B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating	MT

Evolution of the Average Target: Anika Therapeutics, Inc.

Evolution of the Target Price: Anika Therapeutics, Inc.

Changes in Analyst Recommendations: Anika Therapeutics, Inc.

191b3f06c9fd0d4fc004.MxJwhRQ_YJg4heUhJ-xqih5WhoKQUSNGdjf3hI58bKU.Y3Az5yZ0M_9C1qBFVNgI7kE__MOpJ3InB1i_47k_M-JXIArrJ3sV6QjGqA~6cd56932fc5a0957a4a7d76241d650aa

Analysts' recommendations: Anika Therapeutics, Inc.

09-18	B. Riley Adjusts Anika Therapeutics Price Target to $23 From $21, Maintains Buy Rating	MT
07-30	B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating	MT
07-30	Barrington Raises Price Target on Anika Therapeutics to $21 From $17, Keeps Outperform Rating	MT
02-27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
02-27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT
25-07-30	Anika Therapeutics Q2 revenue falls 8%; Hyalofast trial misses main goal	RE
25-05-12	Barrington Adjusts Anika Therapeutics Price Target to $19 From $20, Maintains Outperform Rating	MT
25-04-17	B. Riley Initiates Anika Therapeutics at Buy With $21 Price Target	MT
24-03-14	Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating	MT
24-01-04	Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating	MT
23-11-03	Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating	MT
23-08-14	Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Saying 'Downdraft in Shares Seems Materially Overdone,' Price Target is $24	MT
23-08-10	Stephens Adjusts Price Target on Anika Therapeutics to $23 From $28, Maintains Equal-Weight Rating	MT
23-03-07	Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform After Full-Year 2023 Forecast Below Expectations	MT
23-03-07	Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform	MT
22-11-09	Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31	MT
22-10-14	Stephens Reinstates Anika Therapeutics at Equalweight With $26 Price Target	MT
22-03-09	Stephens Downgrades Anika Therapeutics to Equalweight from Overweight, Adjusts Price Target to $35 from $50	MT
21-11-16	Stephens Starts Anika Therapeutics at Overweight With $55 Price Target	MT
21-11-05	Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating	MT
21-07-16	Anika Therapeutics : UBS Starts Anika Therapeutics at Neutral With $46 Price Target	MT
20-12-16	Anika Therapeutics : Barrington Research Upgrades Anika Therapeutics to Outperform From Market Perform; Price Target is $43	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
ANIKA THERAPEUTICS, INC.	-	-	+7.38%
ABBOTT LABORATORIES			+14.29%
STRYKER CORPORATION			+18.06%
MEDTRONIC PLC			+9.65%
ESSILORLUXOTTICA			+19.16%
CENCORA, INC.			+11.51%
HOYA CORPORATION			+17.34%
BECTON, DICKINSON AND COMPANY			-1.68%
IDEXX LABORATORIES, INC.			+24.56%
ALCON INC.			+29.2%
Average			+14.95%
Weighted average by Cap.			+14.87%